The phosphorylation subsequently led to c‐MYC oncogenic activity in T cell lymphoma (TCL).[14] These prior results suggest targeting CAMKIIγ as a potential therapy for TCL with c‐Myc dysregulation. This evidence concerns the gene MYC and T-cell non-Hodgkin lymphoma.